Kaleido

Specialty and rare diseases have undefined patient populations, with individuals who are undiagnosed or misdiagnosed, healthcare providers who are unaware of disease states and their manifestations, as well as treatment journeys that are not well understood. IPM.ai is an Insights-as-a-Service (IaaS) company that empowers the world’s leading life sciences brands to better understand and improve the lives of patients through the development, clinical study, and commercialization of therapeutic interventions. Maximize commercialization efforts by forecasting market size, competitive landscape, and potential ROI. Uncover ideal patients who are undiagnosed and/or misdiagnosed who may be appropriate for disease interception and therapeutic intervention. Statistically model the number of disease cases present in a particular patient population at a given time. Identify physicians who diagnose and treat ideal patients and influence other health care providers.

Rare diseases are often not well studied and there is a limited understanding of many of the aspects necessary to support a drug discovery program. Our AI platform, Healnet, overcomes these challenges by analyzing millions of drug and disease data points to find novel connections that could be turned into new treatment opportunities. By applying frontier technologies across the discovery and development pipeline, we can run multiple stages in parallel and at scale. One disease, one target, one drug: it's an overly simple model, yet it's the one used by nearly all pharmaceutical companies. The next generation of drug discovery is AI-powered, parallel and hypothesis-free. Bringing together the key three drug discovery paradigms.